TRIAL DESIGN AND CONTROL OF ANTIHYPERTENSIVE IN CLINICAL RESEARCH
3. ASSESSMENT OF SAFETY
ICH E-1 suggests that a database of about 1500 patients (300-600 for 6 months, 100 for 1 year) is usually sufficient for chronically administered drugs, but as suggested in that guideline; this may be too small for the very long, very wide exposure in an asymptomatic population intended for antihypertensive drugs.  In addition to the usual safety assessments, attention should be paid to excessive fall in blood pressure (hypotension), especially on standing (orthostatic hypotension), and rebound phenomena. Depending on the particular drug and other observations, studies of effects on heart rhythm or cardiac conduction, coronary steal effects, effects on risk factors for cardiovascular disease (e.g., blood glucose, lipids), and effects on target organ damage are of interest.
4. CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES
As antihypertensive treatments are often used in combination, it is important to study the efficacy and safety of the new drug in this situation. Information on combination use can be obtained in formal factorial studies and in combined use in the course of long- and short-term clinical studies. Specific requirements regarding clinical co-administration studies may vary among regions. Studies in patients with inadequate blood pressure control on other agents will provide information on the effect of the test drug when added to other agents (add on studies). Studies in which additional drugs are added to the test drug to achieve an adequate response may also be useful.
5. FIXED COMBINATION PRODUCTS
There are two approaches to the combination studies needed to obtain safety and efficacy data to support fixed combination products. It is essential to consult with regional regulatory authorities regarding the specific data needed to support the specific indications.
5.1 Factorial study: In a factorial study, placebo, and one or more doses of the test drug T and another drug D are studied alone and in the combination in a short-term randomized controlled trial. Such a trial can be used to show that the combination has a greater effect than either drug alone. Most informative for identifying the appropriate dosages for a fixed combination is a factorial D/R study in which several doses of each drug, e.g., a test drug T and another drug D, and their combinations are compared, as shown below.
This design reveals D/R relationships for the test drug and other drug alone and in combination with each dose of the other treatment and may support one or more fixed combinations. These studies reveal "response surface" relationships that use data from all groups. It may be necessary to study separately the low doses and low dose combinations to establish their specific usefulness.
5.2 Studies in non-responders to each drug
The safety and efficacy of combinations can also be assessed by examining the effect of the combination in patients failing to respond to both of the single drugs, e.g., diastolic blood pressure > 90 mmHg on that component. In some cases, regional authorities only require trials in patients failing to respond to one of the components.
This article deals with control and design principles that guide the conduct and conclusion of a meaningful HT trial. The international guidelines and current clinical and biostatistical practices were reviewed for relevant clinical, design, end-point assessments and regulatory issues.
The results are grouped mainly into ethical, protocol and assessment issues. Each trial is as meaningful as the number of scientific questions it answers and paves the direction of future trials in that field.
Compliance to GCP opens up the data for correct interpretation. Any neglect toward this end of abiding by the GCP principles can raise a batch of critical questions, eventually rendering the entire data to be uninteresting or suspect.
Principles of study design and analysis mentioned in this article can give the trial lists an advantage of a well-designed study, providing the crucial evidence of safety and efficacy of the agent under testing.
1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217–23
2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22:11–9.
3. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: What was wrong with doxazosin in the ALLHAT? Curr Control Trials Cardiovasc Med. 2001;2:257–9.
4. Rahn KH. Recent intervention studies with antihypertensive drugs and their influence on guidelines.Med Klin. 2003;98:771–5.
5. Centre for Drug Evaluation and Research, USA Food and Drug Administration. Guidance for industry - E12A: Principles for Clinical Evaluation of New Antihypertensive Drugs. 2002 Available
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.(RENAAL) N Engl J Med. 2001;345:861–9.
7. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet.2005;366:895–906.
8. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med2002;346:896–903.
9. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med2002;347:322–329.
10. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125.
11. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–447.
12. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med2005;353:2148–2157.
13. Center for Drug Evaluation and Research. Medical review of application #22–081: Ambrisentan. Center for Drug Evaluation and Research; 2007.
14. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.
15. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming T, Burgess G, Collings L, Cossons N, Badesch DB. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2007;175:A300.
16. EARLY: first functional class II population study emphasizes need to diagnose and treat PAH early [media release]. Allschwil, Switzerland: Actelion Pharmaceuticals; 2007.
NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.
SUBMIT YOUR ARTICLE/PROJECT AT email@example.com
FIND OUT MORE ARTICLES AT OUR DATABASE